Key facts
- It has raised $10.6M across 8 recorded rounds; the latest was Seed Round ($1.0M) in Jul 2025.
- Notable investors include US National Science Foundation.
- BioProtonics has filed 17 Form Ds with the SEC since 2019, most recently Jul 2025 ($150K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BioProtonics
Funding rounds
8 roundsAbout BioProtonics
Developer of an MR-based diagnostic platform designed to offer a non-invasive and in vivo measure to indicate the onset of a disease. The company's platform provides the resolving power needed to non-invasively measure the ultra-fine tissue changes that are the earliest harbingers of disease, and the sensitive measure of disease progression, enabling doctors to have the effective application of therapeutics.
- Sector
- Healthcare
- HQ
- Santa Barbara, CA, United States
- Founded
- 2014
- Employees
- 9
- Website
- bioprotonics.com/
- Ownership
- Privately Held (backing)
BioProtonics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioProtonics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioProtonics in its N-PORT filings yet. We sweep new filings monthly.